TABLE 3.

Absorbed Dose to Red Marrow Estimated Using Image-Based Activity Concentrations in T9–L5 Vertebrae, Hip Bones, and Thoracic Aorta

Patient no.	Bone metastases	Vertebrae			Hip bones			Blood-based (skeletal average)
		Specific	Nonspecific	Total	Specific	Nonspecific	Total
1	No	0.068	0.026	0.093	0.066	0.019	0.085	0.015
2	No	0.025	0.019	0.044	0.016	0.014	0.030	0.011
3	Yes	0.016	0.018	0.033	0.028	0.013	0.042	0.012
4	No	0.022	0.014	0.036	0.014	0.011	0.025	0.010
5*	Yes	0.496	0.028	0.524	0.251	0.022	0.273	0.019
6	No	0.018	0.016	0.034	0.022	0.012	0.034	0.011
7	No	0.020	0.023	0.042	0.012	0.017	0.028	0.017
8	No	0.029	0.021	0.050	0.039	0.015	0.054	0.012
9	No	0.038	0.024	0.062	0.028	0.017	0.045	0.013
10	No	0.047	0.023	0.070	0.024	0.017	0.040	0.013
11	Yes	0.065	0.041	0.106	0.049	0.030	0.079	0.023
12	Yes	0.052	0.025	0.077	0.040	0.018	0.058	0.014
13	No	0.052	0.041	0.093	0.030	0.030	0.059	0.023
14	Yes	0.056	0.037	0.093	0.069	0.027	0.096	0.021
15	Yes	0.114	0.042	0.157	0.084	0.032	0.116	0.029
16	Yes	0.026	0.013	0.039	0.020	0.010	0.030	0.009
17	No	0.043	0.043	0.086	0.052	0.033	0.085	0.029

^*Removed from all averages because of large number of bone metastases.

Data are Gy/GBq. For vertebrae and hip bones, absorbed dose contributions were divided into specific (somatostatin receptor type 2–based) and nonspecific (blood-based, Eq. 4). Equation 5 was used for solely blood-based dosimetry in right column.